Evidence mapPaperPMID 36314488Full record

ArticleJournal of the American Heart Association2022

Circulating Soluble CD163, Associations With Cardiovascular Outcomes and Mortality, and Identification of Genetic Variants in Older Individuals: The Cardiovascular Health Study.

Peter Durda, Laura M Raffield, Ethan M Lange, Nels C Olson, Nancy Swords Jenny, Mary Cushman, Pia Deichgraeber, Niels Grarup, Anna Jonsson, Torben Hansen and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. CD163Basic research in cardiology · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Peter DurdaDepartment of Pathology and Laboratory Medicine Larner College of Medicine, University of Vermont Burlington VT.ORCID 0000-0003-4000-2943
Laura M RaffieldDepartment of Genetics University of North Carolina Chapel Hill NC.ORCID 0000-0002-7892-193X
Ethan M LangeDivision of Biomedical Informatics and Personalized Medicine, Department of Medicine University of Colorado Anschutz Medical Campus Aurora CO.ORCID 0000-0001-7075-4287
Nels C OlsonDepartment of Pathology and Laboratory Medicine Larner College of Medicine, University of Vermont Burlington VT.ORCID 0000-0003-1192-9969
Nancy Swords JennyDepartment of Pathology and Laboratory Medicine Larner College of Medicine, University of Vermont Burlington VT.
Mary CushmanDepartment of Pathology and Laboratory Medicine Larner College of Medicine, University of Vermont Burlington VT.ORCID 0000-0002-7871-6143
Pia DeichgraeberSteno Diabetes Center Aarhus University Hospital Aarhus Denmark.ORCID 0000-0003-0367-7968
Niels GrarupNovo Nordisk Foundation Center for Basic Metabolic Research Copenhagen Denmark.ORCID 0000-0001-5526-1070
Anna JonssonNovo Nordisk Foundation Center for Basic Metabolic Research Copenhagen Denmark.ORCID 0000-0003-1252-8673
Torben HansenNovo Nordisk Foundation Center for Basic Metabolic Research Copenhagen Denmark.
Josyf C MychaleckyjCenter for Public Health Genomics University of Virginia Charlottesville VA.ORCID 0000-0003-2595-0005
Bruce M PsatyCardiovascular Health Research Unit, Departments of Medicine, Epidemiology and Health Services University of Washington Seattle WA.ORCID 0000-0002-7278-2190
Alex P ReinerDepartment of Epidemiology University of Washington Seattle WA.ORCID 0000-0002-1427-4470
Russell P TracyDepartment of Pathology and Laboratory Medicine Larner College of Medicine, University of Vermont Burlington VT.ORCID 0000-0002-0080-2420
Leslie A LangeDivision of Biomedical Informatics and Personalized Medicine, Department of Medicine University of Colorado Anschutz Medical Campus Aurora CO.
University of Vermont · USNovo Nordisk Foundation · DKUniversity of Colorado Anschutz Medical Campus · USUniversity of Washington · USSteno Diabetes Centers · DKUniversity of North Carolina at Chapel Hill · USUniversity of Virginia · US

Funding

Exceptional aging: 12 year trajectories to functionR01AG023629 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2004 to 2005
$2.6M
CHS Events Follow-up StudyU01HL080295 · UNIVERSITY OF WASHINGTON · 2005 to 2005
$1.1M
The Genetic Epidemiology of Heart, Lung, and Blood Traits Training Grant (GenHLB)T32HL129982 · UNIV OF NORTH CAROLINA CHAPEL HILL · 2025 to 2025
$278k
NCATS NIH HHS KL2 TR002490NHLBI NIH HHS 75N92021D00006NHLBI NIH HHS HHSN268200800007CNHLBI NIH HHS HHSN268201200036CNHLBI NIH HHS HHSN268201800001CNHLBI NIH HHS N01HC85079NHLBI NIH HHS N01HC85081NHLBI NIH HHS N01HC85082NHLBI NIH HHS N01HC85086NHLBI NIH HHS R01 HL080295NHLBI NIH HHS R01 HL105756NHLBI NIH HHS R01 HL132947NHLBI NIH HHS T32 HL129982NHLBI NIH HHS U01 HL080295NHLBI NIH HHS U01 HL130114NIA NIH HHS R01 AG023629
6 · The paper itself

Abstract

Background Monocytes/macrophages participate in cardiovascular disease. CD163 (cluster of differentiation 163) is a monocyte/macrophage receptor, and the shed sCD163 (soluble CD163) reflects monocyte/macrophage activation. We examined the association of sCD163 with incident cardiovascular disease events and performed a genome-wide association study to identify sCD163-associated variants. Methods and Results We measured plasma sCD163 in 5214 adults (aged ≥65 years, 58.7% women, 16.2% Black) of the CHS (Cardiovascular Health Study). We used Cox regression models (associations of sCD163 with incident events and mortality); median follow-up was 26 years. Genome-wide association study analyses were stratified on race. Adjusted for age, sex, and race and ethnicity, sCD163 levels were associated with all-cause mortality (hazard ratio [HR], 1.08 [95% CI, 1.04-1.12] per SD increase), cardiovascular disease mortality (HR, 1.15 [95% CI, 1.09-1.21]), incident coronary heart disease (HR, 1.10 [95% CI, 1.04-1.16]), and incident heart failure (HR, 1.18 [95% CI, 1.12-1.25]). When further adjusted (eg, cardiovascular disease risk factors), only incident coronary heart disease lost significance. In European American individuals, genome-wide association studies identified 38 variants on chromosome 2 near

Indexed as

Antigens, CDCardiovascular DiseasesHeart FailureAgedAntigens, Differentiation, MyelomonocyticAsialoglycoprotein ReceptorBiomarkersCD163 AntigenFemaleGenome-Wide Association StudyHumansLongitudinal StudiesMaleAntigens, CDAntigens, Differentiation, MyelomonocyticASGR1 protein, humanAsialoglycoprotein ReceptorBiomarkersCD163 Antigencardiovascular diseasesCD163 antigengenome‐wide association studyhumansmonocytesrisk factors

Identifiers

PMID36314488
PMCPMC9673628
OpenAlexW4308017658

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.